Landmark trial
Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non–Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial
Bezjak A, Paulus R, Gaspar LE, et al. · NRG Oncology / RTOG
DoseLab summary
Seamless phase 1/2 dose-escalation trial of five-fraction SBRT for centrally located early-stage non-small cell lung cancer. The protocol's definition of a “central” tumor is widely referenced.
Why this is useful
The reference trial for centrally located lung tumors — where the proximal bronchial tree, esophagus, heart and great vessels become the limiting structures.
Reference details
- Title
- Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non–Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial
- Authors / organization
- Bezjak A, Paulus R, Gaspar LE, et al. · NRG Oncology / RTOG
- Publication / protocol
- J Clin Oncol. 2019;37(15):1316–1325
- Version
- Pending verification
- Year
- 2019
- DOI
- 10.1200/JCO.18.00622
- Disease sites
- Lung
- Topics
- SBRT, Landmark trial, RTOG, NRG, Central tumors
- Fractionation context
- SBRT (5 fractions)
- Last reviewed by DoseLab
- Pending verification